Anakinra

證據等級: L5

預測適應症: 10 個

Anakinra: From Autoinflammatory Disorders to Extracutaneous Mastocytoma

One-Sentence Summary

Anakinra is a recombinant human interleukin-1 receptor antagonist (IL-1Ra), globally recognized as a treatment for rheumatoid arthritis and hereditary autoinflammatory syndromes. The TxGNN model assigns its highest-ranked prediction to Extracutaneous Mastocytoma with a score of 99.93%; however, no clinical trials and no published literature currently support this direction, making this a model-only signal.

Quick Overview

Item	Content
Original Indication	Not available from local registration (no Saudi Arabia authorization on file)
Predicted New Indication	Extracutaneous Mastocytoma
TxGNN Prediction Score	99.93%
Evidence Level	L5
Saudi Arabia Market Status	Not marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this Evidence Pack. Based on established pharmacological knowledge, Anakinra (Kineret) functions as a recombinant human IL-1 receptor antagonist — competitively blocking both IL-1α and IL-1β from binding to the IL-1 type I receptor. This mechanism underlies its proven efficacy in IL-1-driven conditions such as rheumatoid arthritis, systemic juvenile idiopathic arthritis (sJIA), neonatal-onset multisystem inflammatory disease (NOMID), and hereditary periodic fever syndromes.

Extracutaneous mastocytoma is a rare soft-tissue neoplasm characterized by clonal proliferation of mast cells outside the skin. The dominant pathogenic driver is a KIT gain-of-function mutation (most commonly D816V), which causes constitutive activation of the KIT receptor tyrosine kinase — an oncogenic mechanism entirely distinct from IL-1–mediated inflammation. While mast cells do secrete IL-1 and participate in inflammatory networks, IL-1 signaling is a secondary environmental feature rather than the core oncogenic event.

The TxGNN model's high prediction score (0.999) for this pairing most plausibly reflects disease network topological proximity — extracutaneous mastocytoma sits near other mast cell activation and autoinflammatory nodes in the biological knowledge graph — rather than a direct pharmacological rationale. Without any preclinical, translational, or clinical evidence to support IL-1 blockade in mastocytoma, this prediction should be treated as a hypothesis-generating signal only, not an actionable repurposing candidate.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: Despite the TxGNN model's high prediction score, the mechanistic link between anakinra's IL-1Ra activity and extracutaneous mastocytoma (a KIT-mutation-driven neoplasm) is indirect at best. The complete absence of any supporting clinical trial or published literature means there is no empirical basis to advance this indication at this time.

To proceed, the following is needed:

Preclinical evidence establishing a functional role of IL-1 signaling in extracutaneous mastocytoma tumor biology or microenvironment
Mechanistic data (MOA) for anakinra retrieved from DrugBank API or an approved product monograph
Safety profile review from SFDA, EMA, or FDA package insert (currently a blocking data gap)
Re-evaluation of whether TxGNN network topology proximity correlates with any known mast cell–IL-1 co-regulatory axis

Note: While the top TxGNN prediction (rank 1) warrants a Hold, higher-quality evidence exists for other predicted indications in this pack — notably autosomal recessive familial Mediterranean fever (rank 3, L3, Proceed with Guardrails) and pyogenic autoinflammatory syndrome / PAPA spectrum (rank 9, L3, Proceed with Guardrails) — both of which have direct mechanistic alignment with anakinra's IL-1Ra activity and are supported by published literature including at least one systematic review. Those indications may be more actionable for follow-on evaluation.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.